MCID: IND016
MIFTS: 36

Indolent B-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Indolent B-Cell Non-Hodgkin Lymphoma

MalaCards integrated aliases for Indolent B-Cell Non-Hodgkin Lymphoma:

Name: Indolent B-Cell Non-Hodgkin Lymphoma 58
Indolent B-Cell Nhl 58

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Orphanet 58 ORPHA300842

Summaries for Indolent B-Cell Non-Hodgkin Lymphoma

MalaCards based summary : Indolent B-Cell Non-Hodgkin Lymphoma, also known as indolent b-cell nhl, is related to follicular lymphoma and lymphoma. An important gene associated with Indolent B-Cell Non-Hodgkin Lymphoma is BAK1 (BCL2 Antagonist/Killer 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Human cytomegalovirus infection. The drugs rituximab and ofatumumab have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and breast, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Indolent B-Cell Non-Hodgkin Lymphoma

Diseases related to Indolent B-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 30.2 MCL1 BCL2L1
2 lymphoma 30.0 MCL1 BCL2L1 BAX
3 lymphoma, non-hodgkin, familial 29.7 MCL1 BCL2L1 BAX BAK1
4 b-cell lymphoma 29.2 MCL1 BCL2L1 BAX BAK1
5 leukemia, chronic lymphocytic 29.0 MCL1 BCL2L1 BAX BAK1
6 lymphoma, hodgkin, classic 10.9
7 b-cell non-hodgkin lymphoma 10.9
8 neutropenia 10.8
9 mantle cell lymphoma 10.6
10 lymphocytic leukemia 10.5
11 marginal zone b-cell lymphoma 10.4
12 nodal marginal zone lymphoma 10.4
13 lymphopenia 10.4
14 lymphoma, mucosa-associated lymphoid type 10.2
15 leukemia, acute myeloid 10.2
16 myelodysplastic syndrome 10.2
17 exanthem 10.2
18 lymphoplasmacytic lymphoma 10.2
19 neuroretinitis 10.2
20 thrombocytopenia 10.2
21 constipation 10.2
22 agammaglobulinemia 10.2
23 retinitis 10.2
24 liver cirrhosis 10.2
25 indolent b cell lymphoma 10.2
26 coronavirus infection 9.9 MCL1 BAK1
27 childhood acute lymphocytic leukemia 9.8 MCL1 BAX
28 testicular germ cell tumor 9.8 BAX BAK1
29 apocrine adenosis of breast 9.7 MCL1 BCL2L1
30 acute t cell leukemia 9.7 MCL1 BAX
31 spherocytosis, type 5 9.7 MCL1 BCL2L1
32 alk-negative anaplastic large cell lymphoma 9.6 BCL2L1 BAX
33 maxillary sinus squamous cell carcinoma 9.6 BCL2L1 BAX
34 focal cortical dysplasia, type ii 9.6 BCL2L1 BAX
35 bone marrow cancer 9.5 MCL1 BCL2L1
36 retinal ischemia 9.3 BCL2L1 BAX BAK1
37 leukocyte disease 9.3 MCL1 BCL2L1 BAX
38 breast adenocarcinoma 9.3 BCL2L1 BAX BAK1
39 mesothelioma, malignant 9.2 MCL1 BCL2L1
40 burkitt lymphoma 9.2 MCL1 BCL2L1 BAX
41 myeloid leukemia 9.2 MCL1 BCL2L1 BAX
42 hematologic cancer 9.2 MCL1 BCL2L1 BAX
43 leukemia, acute lymphoblastic 9.2 MCL1 BCL2L1 BAX
44 gastric adenocarcinoma 9.1 MCL1 BCL2L1 BAX
45 glioblastoma multiforme 9.1 MCL1 BCL2L1 BAX
46 cervical cancer 8.9 MCL1 BCL2L1 BAX BAK1
47 pancreatic cancer 8.8 MCL1 BCL2L1 BAX BAK1
48 hepatocellular carcinoma 8.5 MCL1 BCL2L1 BAX BAK1

Graphical network of the top 20 diseases related to Indolent B-Cell Non-Hodgkin Lymphoma:



Diseases related to Indolent B-Cell Non-Hodgkin Lymphoma

Symptoms & Phenotypes for Indolent B-Cell Non-Hodgkin Lymphoma

GenomeRNAi Phenotypes related to Indolent B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.33 BAK1 BAX MCL1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.17 BAX BCL2L1 MCL1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.17 BAK1 BAX BCL2L1 MCL1
4 Synthetic lethal with cisplatin GR00101-A-1 8.96 BCL2L1 MCL1

MGI Mouse Phenotypes related to Indolent B-Cell Non-Hodgkin Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.26 BAK1 BAX BCL2L1 MCL1
2 reproductive system MP:0005389 8.92 BAK1 BAX BCL2L1 MCL1

Drugs & Therapeutics for Indolent B-Cell Non-Hodgkin Lymphoma

Drugs for Indolent B-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3 174722-31-7 10201696
2
ofatumumab Approved Phase 3 679818-59-8 6918251
3 Antibodies, Monoclonal Phase 3
4 Antineoplastic Agents, Immunological Phase 3
5 Antirheumatic Agents Phase 3
6 Immunoglobulins Phase 3
7 Antibodies Phase 3
8 Immunologic Factors Phase 3
9 Alkylating Agents Phase 3
10 Bendamustine Hydrochloride Phase 3
11 Pharmaceutical Solutions Phase 3
12
Ixazomib Approved, Investigational Phase 2 1072833-77-2
13
Sodium citrate Approved, Investigational Phase 2 68-04-2
14
Blinatumomab Approved, Investigational Phase 2 853426-35-4
15
Ledipasvir Approved Phase 2 1256388-51-8 67505836
16
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
17
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
18
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
19
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
20 Neurotransmitter Agents Phase 2
21 HIV Protease Inhibitors Phase 2
22
protease inhibitors Phase 2
23 Citrate Phase 2
24 Anticoagulants Phase 2
25 Chelating Agents Phase 2
26 Calcium, Dietary Phase 2
27 Antibodies, Bispecific Phase 2
28 Anti-Infective Agents Phase 2
29 Antiviral Agents Phase 2
30 Ledipasvir, sofosbuvir drug combination Phase 2
31 Hepatitis C Antibodies Phase 2
32
Idelalisib Approved Phase 1 870281-82-6
33
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
34
Chlorambucil Approved Phase 1 305-03-3 2708
35
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
36
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
37
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
38
Lenalidomide Approved Phase 1 191732-72-6 216326
39
Vidarabine Approved, Investigational Phase 1 24356-66-9 32326 21704
40
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
41
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
42
Aldesleukin Approved Phase 1 110942-02-4, 85898-30-2
43
Vincristine Approved, Investigational Phase 1 2068-78-2, 57-22-7 5978
44 Angiogenesis Inhibitors Phase 1
45 Antibiotics, Antitubercular Phase 1
46 Anti-Bacterial Agents Phase 1
47 Antifungal Agents Phase 1
48 Antimetabolites Phase 1
49 Immunosuppressive Agents Phase 1
50 Analgesics Phase 1

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
2 A Prospective, Randomized, Open-label, Multi-center Study of Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma: Wuhan University Cancer Center -NHL02 Trial Recruiting NCT02438501 Phase 3
3 A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab Terminated NCT01289223 Phase 3 Bendamustine IV
4 Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy Terminated NCT01200589 Phase 3
5 Randomized Open Label of Ofatumumab and Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment Terminated NCT01077518 Phase 3 Ofatumumab (Arm A);Bendamustine infusion (Arm B);Bendamustine infusion (Arm A)
6 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcYRIIB), in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab Recruiting NCT03571568 Phase 1, Phase 2
7 A Window Study of Ixazomib in Untreated Indolent B-NHL Recruiting NCT02339922 Phase 2 Ixazomib Citrate
8 A Phase II Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma Recruiting NCT02811679 Phase 2 Blinatumomab
9 A Phase 1/2 Study of ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab Active, not recruiting NCT02384954 Phase 1, Phase 2
10 A Pilot Phase II Study of New Direct-Acting Antiviral Agent, HARVONI® (Ledipasvir/Sofosbuvir), for the Treatment of Genotype 1 or 2 HCV-Associated Indolent B-Cell Non- Hodgkin's Lymphoma Not yet recruiting NCT03261349 Phase 2 Ledipasvir and sofosbuvir
11 A Phase I/II Trial of Rituximab, Bendamustine, and Obatoclax in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Withdrawn NCT01238146 Phase 1, Phase 2 bendamustine hydrochloride;obatoclax mesylate
12 A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia Completed NCT01088048 Phase 1 Idelalisib;Rituximab;Bendamustine;Ofatumumab;Fludarabine;Everolimus;Bortezomib;Chlorambucil;Lenalidomide
13 Phase I Trial to Assess the Safety and Pharmacokinetics of GP2013 Monotherapy Administered Weekly in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma Completed NCT01933516 Phase 1 GP2013
14 A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia Completed NCT01410513 Phase 1 SAR245409
15 A Pilot Study to Evaluate the Safety and Feasibility of Cellular Immunotherapy Using Genetically Modified Autologous CD20-Specific T Cells For Patients With Relapsed or Refractory Mantle Cell and Indolent B Cell Lymphomas Completed NCT00621452 Phase 1 cyclophosphamide
16 BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma Recruiting NCT02257242 Phase 1 Rituximab;Bendamustine;Vincristine sulfate liposome injection
17 A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma Active, not recruiting NCT02207062 Ibrutinib

Search NIH Clinical Center for Indolent B-Cell Non-Hodgkin Lymphoma

Genetic Tests for Indolent B-Cell Non-Hodgkin Lymphoma

Anatomical Context for Indolent B-Cell Non-Hodgkin Lymphoma

MalaCards organs/tissues related to Indolent B-Cell Non-Hodgkin Lymphoma:

40
B Cells, T Cells, Breast, Myeloid, B Lymphoblasts, Bone Marrow, Bone

Publications for Indolent B-Cell Non-Hodgkin Lymphoma

Articles related to Indolent B-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 89)
# Title Authors PMID Year
1
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result. 61
31838764 2019
2
Where does transplant fit in the age of targeted therapies? 61
31808860 2019
3
Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. 61
31640581 2019
4
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. 61
31127456 2019
5
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. 61
30693983 2019
6
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. 61
30938714 2019
7
MALT Lymphoma as a Model of Chronic Inflammation-Induced Gastric Tumor Development. 61
31123886 2019
8
Burden of illness of follicular lymphoma and marginal zone lymphoma. 61
30315345 2019
9
A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma. 61
29233743 2018
10
T follicular helper cells: a potential therapeutic target in follicular lymphoma. 61
29340116 2017
11
Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation. 61
28561902 2017
12
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan. 61
27900638 2017
13
Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden. 61
27896571 2017
14
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate. 61
27587710 2017
15
B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains. 61
27750045 2016
16
Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden. 61
27714587 2016
17
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. 61
27293194 2016
18
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. 61
27101934 2016
19
Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. 61
25111959 2015
20
Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation. 61
26390162 2015
21
Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations. 61
26498442 2015
22
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. 61
26282650 2015
23
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. 61
25712458 2015
24
Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma. 61
26006703 2015
25
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. 61
25783753 2015
26
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. 61
26687959 2015
27
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. 61
25630297 2015
28
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. 61
25596263 2015
29
Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma. 61
25963431 2015
30
Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas. 61
25511319 2015
31
Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. 61
26196236 2015
32
Progression and Transformation of Clonally Heterogeneous B-cell Lymphoma. 61
26068800 2015
33
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. 61
24927856 2014
34
Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT. 61
23996464 2014
35
[Metabolic activity measured by ¹⁸F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype]. 61
25511487 2014
36
Simultaneous determination of bendamustine and its active metabolite, gamma-hydroxy-bendamustine in human plasma and urine using HPLC-fluorescence detector: application to a pharmacokinetic study in Chinese cancer patients. 61
24793082 2014
37
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. 61
24617454 2014
38
Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). 61
24870874 2014
39
Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. 61
24333758 2014
40
Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands. 61
24038025 2014
41
microRNA levels in paraffin-embedded indolent B-cell non-Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virus. 61
25236768 2014
42
Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series. 61
24060287 2013
43
Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma. 61
23652586 2013
44
Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors. 61
23797978 2013
45
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 61
23246162 2013
46
Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China. 61
22430608 2012
47
Radioimmunotherapy for B-cell non-hodgkin lymphomas. 61
22710895 2012
48
MALT lymphomas: pathogenesis can drive treatment. 61
22229204 2011
49
Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study. 61
21645173 2011
50
Bendamustine: mechanism of action and clinical data. 61
22362008 2011

Variations for Indolent B-Cell Non-Hodgkin Lymphoma

Expression for Indolent B-Cell Non-Hodgkin Lymphoma

Search GEO for disease gene expression data for Indolent B-Cell Non-Hodgkin Lymphoma.

Pathways for Indolent B-Cell Non-Hodgkin Lymphoma

Pathways related to Indolent B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 MCL1 BCL2L1 BAX BAK1
2
Show member pathways
12.58 BCL2L1 BAX BAK1
3
Show member pathways
12.57 BCL2L1 BAX BAK1
4
Show member pathways
12.52 BCL2L1 BAX BAK1
5 12.49 BCL2L1 BAX BAK1
6
Show member pathways
12.47 BCL2L1 BAX BAK1
7
Show member pathways
12.46 MCL1 BCL2L1 BAX BAK1
8 12.44 BCL2L1 BAX BAK1
9
Show member pathways
12.41 BCL2L1 BAX BAK1
10 11.98 BCL2L1 BAX BAK1
11 11.94 MCL1 BCL2L1 BAX BAK1
12 11.83 BAX BAK1
13 11.82 MCL1 BAX BAK1
14
Show member pathways
11.76 BCL2L1 BAX BAK1
15 11.69 BAX BAK1
16 11.68 MCL1 BCL2L1
17
Show member pathways
11.68 BCL2L1 BAX
18 11.62 BCL2L1 BAX BAK1
19
Show member pathways
11.55 MCL1 BCL2L1
20
Show member pathways
11.54 MCL1 BCL2L1 BAX BAK1
21 11.47 BCL2L1 BAX BAK1
22 11.16 MCL1 BCL2L1 BAX BAK1
23
Show member pathways
11.11 MCL1 BCL2L1 BAX BAK1
24 11.06 BCL2L1 BAX
25 10.94 BCL2L1 BAX BAK1
26 10.89 MCL1 BCL2L1
27 10.82 MCL1 BCL2L1 BAX BAK1

GO Terms for Indolent B-Cell Non-Hodgkin Lymphoma

Cellular components related to Indolent B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.67 MCL1 BCL2L1 BAX BAK1
2 mitochondrial membrane GO:0031966 9.43 BCL2L1 BAX BAK1
3 pore complex GO:0046930 9.32 BAX BAK1
4 mitochondrial outer membrane GO:0005741 9.26 MCL1 BCL2L1 BAX BAK1
5 BAK complex GO:0097145 9.16 BAX BAK1
6 Bcl-2 family protein complex GO:0097136 8.92 MCL1 BCL2L1 BAX BAK1

Biological processes related to Indolent B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.81 MCL1 BCL2L1 BAX BAK1
2 cell proliferation GO:0008283 9.8 BCL2L1 BAX BAK1
3 regulation of cell cycle GO:0051726 9.71 BAX BAK1
4 negative regulation of neuron apoptotic process GO:0043524 9.71 BCL2L1 BAX
5 male gonad development GO:0008584 9.71 BCL2L1 BAX
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.7 BAX BAK1
7 apoptotic signaling pathway GO:0097190 9.7 BAX BAK1
8 response to cytokine GO:0034097 9.7 MCL1 BCL2L1
9 cellular response to UV GO:0034644 9.7 BAX BAK1
10 fertilization GO:0009566 9.69 BCL2L1 BAX
11 neuron apoptotic process GO:0051402 9.69 BCL2L1 BAX
12 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.69 BCL2L1 BAX
13 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.68 MCL1 BCL2L1
14 ovarian follicle development GO:0001541 9.68 BCL2L1 BAX
15 germ cell development GO:0007281 9.68 BCL2L1 BAX
16 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress GO:0070059 9.68 BAX BAK1
17 blood vessel remodeling GO:0001974 9.67 BAX BAK1
18 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.67 BAX BAK1
19 response to gamma radiation GO:0010332 9.67 BAX BAK1
20 negative regulation of intrinsic apoptotic signaling pathway GO:2001243 9.66 MCL1 BCL2L1
21 cellular response to unfolded protein GO:0034620 9.66 BAX BAK1
22 negative regulation of peptidyl-serine phosphorylation GO:0033137 9.65 BAX BAK1
23 limb morphogenesis GO:0035108 9.65 BAX BAK1
24 mitochondrion morphogenesis GO:0070584 9.65 BCL2L1 BAX
25 homeostasis of number of cells GO:0048872 9.64 BAX BAK1
26 B cell homeostasis GO:0001782 9.64 BAX BAK1
27 apoptotic mitochondrial changes GO:0008637 9.63 BCL2L1 BAX
28 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.62 BAX BAK1
29 mitochondrial fusion GO:0008053 9.62 BAX BAK1
30 regulation of apoptotic process GO:0042981 9.62 MCL1 BCL2L1 BAX BAK1
31 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.61 BAX BAK1
32 positive regulation of calcium ion transport into cytosol GO:0010524 9.61 BAX BAK1
33 positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway GO:1901030 9.6 BAX BAK1
34 regulation of mitochondrial membrane permeability GO:0046902 9.59 BCL2L1 BAK1
35 vagina development GO:0060068 9.58 BAX BAK1
36 regulation of protein heterodimerization activity GO:0043497 9.58 BAX BAK1
37 negative regulation of endoplasmic reticulum calcium ion concentration GO:0032471 9.57 BAX BAK1
38 myeloid cell homeostasis GO:0002262 9.56 BAX BAK1
39 positive regulation of IRE1-mediated unfolded protein response GO:1903896 9.55 BAX BAK1
40 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.54 BAX BAK1
41 B cell apoptotic process GO:0001783 9.52 BAX BAK1
42 positive regulation of endoplasmic reticulum unfolded protein response GO:1900103 9.49 BAX BAK1
43 thymocyte apoptotic process GO:0070242 9.48 BAX BAK1
44 regulation of protein homodimerization activity GO:0043496 9.46 BAX BAK1
45 apoptotic process involved in blood vessel morphogenesis GO:1902262 9.43 BAX BAK1
46 regulation of mitochondrial membrane potential GO:0051881 9.43 BCL2L1 BAX BAK1
47 post-embryonic camera-type eye morphogenesis GO:0048597 9.4 BAX BAK1
48 B cell negative selection GO:0002352 9.37 BAX BAK1
49 release of cytochrome c from mitochondria GO:0001836 9.33 BCL2L1 BAX BAK1
50 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.26 MCL1 BCL2L1 BAX BAK1

Molecular functions related to Indolent B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.46 MCL1 BCL2L1 BAX BAK1
2 chaperone binding GO:0051087 9.26 BAX BAK1
3 protein heterodimerization activity GO:0046982 9.26 MCL1 BCL2L1 BAX BAK1
4 BH3 domain binding GO:0051434 8.8 MCL1 BCL2L1 BAX

Sources for Indolent B-Cell Non-Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....